FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2553046008> ?p ?o ?g. }

• W2553046008 endingPage "1480" @default.
• W2553046008 startingPage "1469" @default.
• W2553046008 abstract "// Shayahati Bieerkehazhi 1, 2, * , Zhenghu Chen 3, 4, * , Yanling Zhao 4 , Yang Yu 4 , Huiyuan Zhang 4 , Sanjeev A. Vasudevan 5 , Sarah E. Woodfield 5 , Ling Tao 4 , Joanna S. Yi 4 , Jodi A. Muscal 4 , Jonathan C. Pang 4, 6 , Shan Guan 4 , Hong Zhang 2 , Jed G. Nuchtern 5 , Hui Li 7 , Huiwu Li 8 , Jianhua Yang 4 1 Department of Labour Hygiene and Sanitary Science, College of Public Health, Xinjiang Medical University, Urumqi, Xinjiang 830011, P.R. China 2 Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA 3 Department of Ophthalmology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P. R. China 4 Texas Children's Cancer Center, Department of Pediatrics, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA 5 Division of Pediatric Surgery, Texas Children’s Hospital Department of Surgery, Michael E. DeBakey Department of Surgery, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA 6 Department of Biosciences, Weiss School of Natural Sciences, Rice University, Houston, Texas 77005, USA 7 Central Laboratory of Xinjiang Medical University, Urumqi, Xinjiang 830011, P.R. China 8 Cancer Prevention and Research Institute, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, P.R. China * These authors have contributed equally to this work and should be considered co-first authors Correspondence to: Huiwu Li, email: huiwuli1234@163.com Jianhua Yang, email: jianhuay@bcm.edu Keywords: neuroblastoma, bosutinib, SKI-606, Bosulif, chemotherapy Received: October 29, 2016      Accepted: November 12, 2016      Published: November 26, 2016 ABSTRACT Neuroblastoma (NB) is the most common extracranial solid tumor in children. Aberrant activation of the non-receptor tyrosine kinases Src and c-Abl contributes to the progression of NB. Thus, targeting these kinases could be a promising strategy for NB therapy. In this paper, we report that the potent dual Src/Abl inhibitor bosutinib exerts anti-tumor effects on NB. Bosutinib inhibited NB cell proliferation in a dose-dependent manner and suppressed colony formation ability of NB cells. Mechanistically, bosutinib effectively decreased the activity of Src/Abl and PI3K/AKT/mTOR, MAPK/ERK, and JAK/STAT3 signaling pathways. In addition, bosutinib enhanced doxorubicin (Dox)- and etoposide (VP-16)-induced cytotoxicity in NB cells. Furthermore, bosutinib demonstrated anti-tumor efficacy in an orthotopic xenograft NB mouse model in a similar mechanism as of that in vitro . In summary, our results reveal that Src and c-Abl are potential therapeutic targets in NB and that the novel Src/Abl inhibitor bosutinib alone or in combination with other chemotherapeutic agents may be a valuable therapeutic option for NB patients." @default.
• W2553046008 created "2016-11-30" @default.
• W2553046008 creator A5001660190 @default.
• W2553046008 creator A5010485986 @default.
• W2553046008 creator A5020589220 @default.
• W2553046008 creator A5026139057 @default.
• W2553046008 creator A5029157661 @default.
• W2553046008 creator A5041650666 @default.
• W2553046008 creator A5047296464 @default.
• W2553046008 creator A5049161699 @default.
• W2553046008 creator A5058400432 @default.
• W2553046008 creator A5060613926 @default.
• W2553046008 creator A5064785596 @default.
• W2553046008 creator A5065646857 @default.
• W2553046008 creator A5065859286 @default.
• W2553046008 creator A5069849278 @default.
• W2553046008 creator A5076227410 @default.
• W2553046008 creator A5079107035 @default.
• W2553046008 creator A5089000102 @default.
• W2553046008 date "2016-11-26" @default.
• W2553046008 modified "2023-09-30" @default.
• W2553046008 title "Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling" @default.
• W2553046008 cites W1051453527 @default.
• W2553046008 cites W13907802 @default.
• W2553046008 cites W1589166971 @default.
• W2553046008 cites W1590697205 @default.
• W2553046008 cites W1592898600 @default.
• W2553046008 cites W1679250118 @default.
• W2553046008 cites W1719330231 @default.
• W2553046008 cites W1756534494 @default.
• W2553046008 cites W1976220823 @default.
• W2553046008 cites W1977455794 @default.
• W2553046008 cites W1981976777 @default.
• W2553046008 cites W1990848928 @default.
• W2553046008 cites W2002657767 @default.
• W2553046008 cites W2006467763 @default.
• W2553046008 cites W2011858503 @default.
• W2553046008 cites W2014636185 @default.
• W2553046008 cites W2024161072 @default.
• W2553046008 cites W2024951966 @default.
• W2553046008 cites W2031983198 @default.
• W2553046008 cites W2033352665 @default.
• W2553046008 cites W2038772546 @default.
• W2553046008 cites W2042794231 @default.
• W2553046008 cites W2045392955 @default.
• W2553046008 cites W2051381056 @default.
• W2553046008 cites W2051613731 @default.
• W2553046008 cites W2056795440 @default.
• W2553046008 cites W2057375535 @default.
• W2553046008 cites W2059981656 @default.
• W2553046008 cites W2072802467 @default.
• W2553046008 cites W2074018758 @default.
• W2553046008 cites W2080981165 @default.
• W2553046008 cites W2094110307 @default.
• W2553046008 cites W2095296988 @default.
• W2553046008 cites W2096045656 @default.
• W2553046008 cites W2106602239 @default.
• W2553046008 cites W2107972068 @default.
• W2553046008 cites W2114930023 @default.
• W2553046008 cites W2125752165 @default.
• W2553046008 cites W2130278329 @default.
• W2553046008 cites W2142419137 @default.
• W2553046008 cites W2144999788 @default.
• W2553046008 cites W2154975943 @default.
• W2553046008 cites W2165873626 @default.
• W2553046008 cites W2168217578 @default.
• W2553046008 cites W2339231326 @default.
• W2553046008 cites W2404072735 @default.
• W2553046008 cites W2404235140 @default.
• W2553046008 cites W2409050692 @default.
• W2553046008 cites W2467601047 @default.
• W2553046008 cites W2473022707 @default.
• W2553046008 cites W2516837092 @default.
• W2553046008 cites W2526128616 @default.
• W2553046008 cites W2528331586 @default.
• W2553046008 cites W2937913686 @default.
• W2553046008 cites W2992837203 @default.
• W2553046008 cites W6610818 @default.
• W2553046008 doi "https://doi.org/10.18632/oncotarget.13643" @default.
• W2553046008 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5352070" @default.
• W2553046008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27903968" @default.
• W2553046008 hasPublicationYear "2016" @default.
• W2553046008 type Work @default.
• W2553046008 sameAs 2553046008 @default.
• W2553046008 citedByCount "23" @default.
• W2553046008 countsByYear W25530460082017 @default.
• W2553046008 countsByYear W25530460082018 @default.
• W2553046008 countsByYear W25530460082019 @default.
• W2553046008 countsByYear W25530460082020 @default.
• W2553046008 countsByYear W25530460082021 @default.
• W2553046008 countsByYear W25530460082022 @default.
• W2553046008 countsByYear W25530460082023 @default.
• W2553046008 crossrefType "journal-article" @default.
• W2553046008 hasAuthorship W2553046008A5001660190 @default.
• W2553046008 hasAuthorship W2553046008A5010485986 @default.
• W2553046008 hasAuthorship W2553046008A5020589220 @default.
• W2553046008 hasAuthorship W2553046008A5026139057 @default.
• W2553046008 hasAuthorship W2553046008A5029157661 @default.

• next